Search results
Results From The WOW.Com Content Network
The Comprehensive Dangerous Drugs Act of 2002, officially designated as Republic Act No. 9165, is a consolidation of Senate Bill No. 1858 and House Bill No. 4433.It was enacted and passed by the Senate of the Philippines and House of Representatives of the Philippines on May 30 and 29, 2002, respectively.
The cultivation and use of cannabis is illegal in the Philippines under Republic Act 9165 or the Comprehensive Dangerous Drugs Act of 2002. [1] [2] As the Philippines is a signatory to the 1961 United Nations Single Convention on Narcotic Drugs, [3] Cannabis is classified as a Schedule I drug, which limits its use to medical and scientific ...
The agency is tasked with the enforcement of the penal and regulatory provisions of Republic Act No. 9165 (R.A. 9165), otherwise known as the Comprehensive Dangerous Drugs Act of 2002. PDEA is the implementing arm of the Dangerous Drugs Board (DDB). The DDB is the policy-making and strategy-formulating body in the planning and formulation of ...
The Comprehensive Dangerous Drugs Act of 2002 which was signed into law on January 23, 2002 superseded the 1972 anti-drug law which created the DDB's implementing arm the Philippine Drug Enforcement Agency (PDEA) and expanded the DDB into a 17-member body which also include PDEA. In practice however the DDB and PDEA claimed to be the role as ...
In 2025, the works unbound from copyright cap off the 1920s with literature, characters and more from 1929 entering the public domain.
The membership of the board was expanded through the Republic Act 9165. Through the law the Department of the Interior and Local Government, Department of Labor and Employment, Department of Foreign Affairs, Commission on Higher Education, National Youth Commission, and the Philippine Drug Enforcement Agency which was recently established at ...
Below are the primetime rankers for broadcast, cable and premium cable networks in 2024, among total viewers (as well as the top 50 list in adults 18-49).
As the year comes to a close, experts from the Alzheimer's Association reflect on some of the hopeful advances in diagnosis, treatment and risk management that have been made in 2024.